Tuesday, August 4, 2015

Still in Jersey, but Merck moving HQ from Whitehouse Station to Summit

Merck said Tuesday morning that its cost-cutting efforts will now include closing its global headquarters building in Whitehouse Station, N.J. and moving those functions to Summit, N.J.

Still in Jersey, but Merck moving HQ from Whitehouse Station to Summit

0 comments

Merck said Tuesday morning that its cost-cutting efforts will now include closing its global headquarters building in Whitehouse Station, N.J. and moving those functions to Summit, N.J.

Though the company is staying in New Jersey, the move 25 to 30 miles east (depending on the route you drive) will mean a longer commute for some of the employees who live in Pennsylvania so they can pay less in taxes.

The company said about 2,000 employees and contractors currently situated at the Whitehouse Station will move to the facilities in Summit or to other nearby facilities such as those in Branchburg, N.J. and Cokesbury, N.J.

Merck's headquarters was in Whitehouse Station since 1992, after being in Rahway, N.J. Merck got the Summit facility when it bought Schering-Plough in 2009.

"The relocation of our headquarters will help us achieve our future vision, reduce the size of our operating footprint, and increase agility as we adapt to our changing business environment," said Kenneth C. Frazier, a Philly native and Penn State graduate who is chairman and chief executive officer of Merck.

Nothing in the announcement indicated there would be more job cuts at Merck's large facility in West Point, Montgomery County.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter